Capability
Viral Vector CDMOs
Compare CDMOs with viral vector manufacturing capabilities for AAV, lentiviral, retroviral, and adenoviral vector production at GMP scale.
138 companies listed
About Viral Vector Manufacturing
Viral vector manufacturing produces the delivery vehicles for gene therapies and some vaccines. AAV (adeno-associated virus) vectors are the most in-demand, used in approved gene therapies for hemophilia, spinal muscular atrophy, and inherited retinal disease. Lentiviral vectors are used for ex vivo cell therapy manufacturing (CAR-T). Adenoviral vectors serve vaccine platforms.
Production scale and yield are the central challenges. AAV manufacturing typically uses transient transfection of HEK293 cells or baculovirus/Sf9 insect cell systems, with titers significantly lower than monoclonal antibody production. Downstream processing (purification, concentration, formulation) is complex due to the need to separate full from empty capsids, remove host cell DNA, and achieve high purity while maintaining vector potency.
Companies (138)
BioInnovatise, Inc.
United States
BioInnovatise is a US-based CDMO specializing in quick-turnaround molecular biology services for early-stage drug discovery. Services include plasmid DNA services, viral vector packaging, and CRISPR-Cas9 services. The company collaborates with researchers in government, academia, and industry, focusing on custom cloning and the early discovery phase of drug development.
Viral VectorsAnalytical ServicesMethod Development
ABL (ABL, Inc. / ABL Europe)
France
ABL Inc. (also operating as Ascend Advanced Therapies - ABL Inc.) is a biologics CDMO focused on viral vector GMP manufacturing for gene therapies, vaccines, oncolytic viruses, and immunotherapies. They operate facilities in Rockville, MD (USA) and Strasbourg and Lyon (France), with 35+ years of experience. This is the same entity as ABL (ABL, Inc. / ABL Europe), appearing as a duplicate record in the database.
Frequently Asked Questions
What are the main AAV manufacturing platforms?+
Two dominant platforms exist: (1) Transient transfection of HEK293 cells (triple plasmid transfection), which offers flexibility but faces scale-up challenges with plasmid costs and transfection efficiency at large volumes. (2) Baculovirus/Sf9 insect cell system (Bac-to-AAV), which scales more readily in suspension culture but requires baculovirus stock management. A third approach -- stable producer cell lines -- is emerging as a scalable alternative that eliminates the need for plasmid DNA.
Why is the full/empty capsid ratio important?+
AAV manufacturing produces a mixture of full capsids (containing the therapeutic gene) and empty capsids (lacking the gene payload). High empty capsid content reduces potency per dose and may trigger immune responses. Analytical ultracentrifugation (AUC) and cryo-EM are used to measure the full/empty ratio. Downstream purification steps (cesium chloride ultracentrifugation, ion exchange chromatography, or affinity chromatography) separate full from empty capsids, but achieving >80% full capsids remains technically challenging.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
